Retinal Ganglion
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
OCS-05 meets safety, efficacy endpoints in acute optic neuritis trial
OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Severe COVID-19 may impact retina
Retinal ganglion cell layer thickness was significantly reduced in patients with severe COVID-19, which indicates an affinity for nerve cells, according to research published in the Open Journal of Ophthalmology.